Athenex Inc (ATNX) Given Consensus Rating of “Buy” by Analysts

Shares of Athenex Inc (NASDAQ:ATNX) have received a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $20.67.

ATNX has been the topic of several recent research reports. BidaskClub downgraded Athenex from a “hold” rating to a “sell” rating in a research report on Wednesday, March 13th. Royal Bank of Canada reiterated an “outperform” rating on shares of Athenex in a research report on Tuesday, March 12th. Finally, SunTrust Banks started coverage on Athenex in a research report on Friday. They set a “buy” rating and a $20.00 target price on the stock.

Shares of NASDAQ:ATNX opened at $12.25 on Friday. The company has a current ratio of 3.31, a quick ratio of 2.75 and a debt-to-equity ratio of 0.36. Athenex has a 52-week low of $9.83 and a 52-week high of $20.90. The firm has a market capitalization of $831.76 million, a PE ratio of -8.51 and a beta of 0.23.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings data on Monday, March 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.21). Athenex had a negative net margin of 131.81% and a negative return on equity of 66.23%. The company had revenue of $21.27 million during the quarter. On average, equities analysts anticipate that Athenex will post -1.74 EPS for the current fiscal year.

In other Athenex news, CEO Johnson Yiu Nam Lau bought 4,000 shares of Athenex stock in a transaction that occurred on Monday, March 18th. The shares were purchased at an average cost of $12.52 per share, for a total transaction of $50,080.00. Following the completion of the transaction, the chief executive officer now owns 2,936,236 shares of the company’s stock, valued at approximately $36,761,674.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Song-Yi Zhang sold 32,240 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $11.85, for a total value of $382,044.00. Following the transaction, the director now owns 4,000 shares in the company, valued at $47,400. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 57,500 shares of company stock worth $696,090 and have sold 132,240 shares worth $1,559,044. Corporate insiders own 29.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC lifted its position in Athenex by 77.6% during the fourth quarter. Perceptive Advisors LLC now owns 5,096,022 shares of the company’s stock worth $32,550,000 after buying an additional 2,226,494 shares during the period. BlackRock Inc. raised its holdings in shares of Athenex by 0.9% in the 4th quarter. BlackRock Inc. now owns 3,616,333 shares of the company’s stock worth $45,892,000 after purchasing an additional 33,755 shares during the period. Vanguard Group Inc raised its holdings in shares of Athenex by 8.3% in the 3rd quarter. Vanguard Group Inc now owns 1,878,063 shares of the company’s stock worth $29,185,000 after purchasing an additional 144,410 shares during the period. Vanguard Group Inc. raised its holdings in shares of Athenex by 8.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,878,063 shares of the company’s stock worth $29,185,000 after purchasing an additional 144,410 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Athenex by 7.7% in the 4th quarter. Geode Capital Management LLC now owns 489,666 shares of the company’s stock worth $6,213,000 after purchasing an additional 35,061 shares during the period. Hedge funds and other institutional investors own 31.75% of the company’s stock.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.

Featured Article: Buyback For Investors Defined

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.